A Study of PET Adapted Therapy and Non-invasive Monitoring for Previously Untreated Limited Stage Diffuse Large B Cell Lymphoma

The overarching goals of this study are to measure levels of circulating tumor DNA (ctDNA) in patients with early stage diffuse large B cell lymphoma (DLBCL), to assess the change in ctDNA during treatment in order to prospectively identify markers of treatment failure, and to use ctDNA as a future tool for response adapted therapy.

Trial Details

NCT ID
NCT03758989
Phase
PHASE2
Sponsor
University of Rochester
Status
RECRUITING
Cancer Type
Lymphoma
Interventions
  • Rituximab Prednisone
  • Cyclophosphamide
  • Doxorubicin
  • Vincristine
  • Prednisone
Locations (sample)
  • Rochester, New York, United States|43.15478,-77.61556

Key Eligibility Criteria

  • Previously untreated limited stage non bulky DLBCL; defined as limited stage by routine staging criteria in lymphoma involving FDG-PET and bone mar…
  • Patients with grade 3B follicular lymphoma and transformed indolent lymphoma are included
  • Measurable disease, assessable by radiographic examination with FDG-PET showing involvement
  • Access to archived or fresh/frozen tumor biopsies

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lymphoma Trials on Trialify →